

## Translation

# Integration and Reorganization of Overseas Subsidiaries Aiming to Further Accelerate Overseas Business Activities

June 25, 2015 (Tokyo) - Chugai Pharmaceutical Co., Ltd. [Head Office: Chuo-ku, Tokyo; Chairman and CEO: Osamu Nagayama (hereafter, "Chugai")] announced today that it will integrate and reorganize its subsidiaries in Europe, China and Taiwan in order to further accelerate its overseas business activities.

This integration and reorganization have two major purposes. On April 1, 2015, Chugai established the Translational Clinical Research (TCR) Division in order to rapidly acquire early Proof-of-Concept (PoC) for drugs under development that had been discovered and created in-house. The first purpose is to straighten the internal structure as the TCR Division will be in full operation. In addition, until now, the company had separated its activities such as clinical development, import, and sales into respective subsidiary companies depending on the function in each country. By integrating these functions into one company, Chugai will streamline the operations from development to sales and marketing. This will enhance its specialty of each function as well as the competence to collaborate and work together to increase customer satisfaction. The second purpose is to develop Chugai's unique business to provide high value-added services by further strengthening the foundation of its business through this integration and reorganization.

Details of this integration and reorganization in Europe, China and Taiwan are as follows:

### [Europe]


- The business function of Chugai Pharma Europe Ltd., a development subsidiary, will be transferred to Chugai Pharma Marketing Ltd., a sales subsidiary, and the two companies will be integrated as of July 1, 2015.
- Chugai Pharma Europe Ltd. will initiate the liquidation proceedings in due course after completion of transferring procedure.

### 【Overview of the Post-reorganized Company】

- Company name: Chugai Pharma Marketing Ltd.
- Location: Mulliner House, Flanders Road, Turnham Green, London W4 1NN, U.K.
- Capital: 8,677,808 GBP (100% Owned by Chugai)
- Activities: Clinical development, regulatory affairs, medical affairs, import, sales and marketing of pharmaceutical products in Europe

- Representative: John Halls (Managing Director of current Chugai Pharma Marketing Ltd.)
- Number of Employees : 49

**【Reference】 Business functions of pre and post integration and reorganization**




**[China]**

- The business function of Chugai Pharma (Shanghai) Consulting Co., Ltd., a subsidiary that provides academic information on pharmaceutical products, will be transferred to Chugai Pharma China Co., Ltd., a subsidiary that conducts imports, sales and promotion as of July 1, 2015.
- Chugai Pharma (Shanghai) Consulting Co., Ltd. will initiate the liquidation proceedings in due course after completion of transferring procedure.

**【Overview of the Post-reorganized Company】**

- Company name: Chugai Pharma (China) Co., Ltd.
- Location: Building G31, No. 801 Jiankang Dadao, Medical City Taizhou, Jiangsu 225300
- Capital: 30 million USD (100% Owned by Chugai)
- Activities: Import and sales of the pharmaceutical products in China
- Representative: Takashi Sakabe  
(Representative of current Chugai Pharma China Co., Ltd.)
- Number of Employees: 54

**【Reference】 Business functions of pre and post integration and reorganization**




[Taiwan]

- Chugai Pharma R&D Taiwan Ltd., a subsidiary which conducts clinical development and related business activities of products contracted by Chugai or Chugai Pharma Taiwan Ltd., will integrate with Chugai Pharma Taiwan Ltd., a subsidiary specializing in import, sales and marketing of pharmaceutical products as of July 31, 2015.
- Chugai Pharma R&D Taiwan Ltd. will initiate the liquidation proceedings in due course after completion of transferring procedure.

**【Overview of the Post-reorganized Company】**

- Company name: Chugai Pharma Taiwan Ltd.
- Location: 3Fl., No. 73, ZhouZi Street, Neihu District, Taipei 11493 Taiwan
- Capital: 33,376,000 TWD (100% Owned by Chugai)
- Activities: Clinical development, regulatory affairs, import, sales and marketing of the pharmaceutical products in Taiwan
- Representative: Tatsuji Shimada (Representative of current Chugai Pharma Taiwan Ltd. and Department manager of Overseas Business Dept.)
- Number of Employees: 63

**【Reference】 Business functions of pre and post integration and reorganization**



Under its business philosophy “Innovation all for the patients,” Chugai is committed to creating new value through offering innovative medical products and services, thereby contributing to healthcare and human health around the world.